<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: US Men unaware of link between erectile dysfunction and other conditions</title>
	<atom:link href="http://onthepharm.net/2006/06/erectile-dysfunction-diabetes-cholesterol-hypertension.html/feed" rel="self" type="application/rss+xml" />
	<link>http://onthepharm.net/2006/06/erectile-dysfunction-diabetes-cholesterol-hypertension.html</link>
	<description>Life on the pharm</description>
	<pubDate>Fri, 21 Nov 2008 21:46:43 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.3</generator>
		<item>
		<title>By: OnThePharm &#187; It seems Eli Lilly and Amylin have a problem with Byetta</title>
		<link>http://onthepharm.net/2006/06/erectile-dysfunction-diabetes-cholesterol-hypertension.html#comment-49</link>
		<dc:creator>OnThePharm &#187; It seems Eli Lilly and Amylin have a problem with Byetta</dc:creator>
		<pubDate>Wed, 14 Jun 2006 20:10:05 +0000</pubDate>
		<guid isPermaLink="false">http://onthepharm.net/2006/06/erectile-dysfunction-diabetes-cholesterol-hypertension/#comment-49</guid>
		<description>[...] Most problems in medicine and business are bad. But this one is a sign of good things for the two companies: demand for Byetta is outstripping supply. In fact, the companies have asked doctors to not start new patients on the drug until they can get the supply problems ironed out, even going so far as to not give out vouchers and coupons for it. Byetta is one of the more interesting drugs in current diabetes development, and it&#8217;s quite popular because of a welcome side-effect: it tends to cause weight loss in those that take it for an extended period of time. As obesity is one of the factors involved in causing diabetes, this is a double-edged blessing. (An oxymoron if there ever was one, eh?) [...]</description>
		<content:encoded><![CDATA[<p>[...] Most problems in medicine and business are bad. But this one is a sign of good things for the two companies: demand for Byetta is outstripping supply. In fact, the companies have asked doctors to not start new patients on the drug until they can get the supply problems ironed out, even going so far as to not give out vouchers and coupons for it. Byetta is one of the more interesting drugs in current diabetes development, and it&#039;s quite popular because of a welcome side-effect: it tends to cause weight loss in those that take it for an extended period of time. As obesity is one of the factors involved in causing diabetes, this is a double-edged blessing. (An oxymoron if there ever was one, eh?) [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
